1. Scrip
  2. >>Focus On Asia
  3. >>China

15 Chinese Formulation Makers Receive Export Licenses From 29 Nations

Fifteen Chinese formulation producers have recently acquired pharma quality certificates from 29 overseas countries including the U.S., Japan, and 27 European countries.

Fifteen Chinese formulation producers have recently acquired pharma quality certificates from 29 overseas countries including the U.S., Japan, and 27 European countries. The certified companies include Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Zhejiang Huahai Pharmaceuticals Co. Ltd., Lijian Pharmacy Co. Ltd., Zhejiang Jingxin Pharmaceutical Co. Ltd., CSPC Ouyi Pharmaceutical Co. Ltd., Huayi Pharmaceutical (Anhui) Co. Ltd., Shenzhen Gosun Pharmaceutical Co. Ltd., Shenzhen Zhijun Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Hangzhou Minsheng Pharmaceutical Group Co. Ltd., Zhejiang Jinhua CONBA Bio-pharm Co. Ltd., and Youcare Pharmaceutical Group Co. Ltd. China aims to have more than 80 drug companies obtain certification from overseas nations or the World Health Organization by 2016. (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

More from Focus On Asia